PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)

Volume 17, 9 Issues, 2017

Download PDF Flyer

Current Cancer Drug Targets

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 213 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.707
5 - Year: 3.446

PET Imaging with [68Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [18F]Fluorodeoxyglucose and [18F]Fluoroethylcholine

Current Cancer Drug Targets, 14(4): 371-379.

Author(s): Ina Israel, Dominik Richter, Jochen Stritzker, Michaela van Ooschot, Ulrike Donat, Andreas K. Buck and Samuel Samnick.

Affiliation: Department of Nuclear Medicine, University of Wurzburg, Oberdurrbacher Straße 6, D-97080 Wurzburg, Germany.


The αvβ3 integrin is highly expressed in prostate cancer (PCa), in which it is a key player in tumour invasion, angiogenesis and metastasis formation. Therefore, αvβ3 integrin is considered a very promising target for molecular imaging of PCa. This study tested the potential of the novel αvβ3 integrin affine agent [68Ga]NOTA-RGD in comparison with the established [18F]fluoroethylcholine (FEC) and [18F]fluorodeoxyglucose (FDG) for assessing PCa using positron emission tomography (PET). [68Ga]NOTA-RGD showed a lower uptake in PC-3 and DU-145 cells compared with FEC and FDG. µPET imaging studies showed a good delineation of the PCa xenografts in mice. The means tumor-to-muscleand tumor-to-bone-ratio amounted 5.1 ± 1.4 and 5.2 ± 1.2 for [68Ga]NOTA-RGD compared with 2.6 ± 0.9 and 2.9 ± 1.6 for FDG, and 2.4 ± 0.7 and 0.8 ± 0.2 for FEC, respectively. The uptake of [68Ga]NOTA-RGD into tumor was fully inhibited by c(RGDfV), known to bind specifically to αvβ3 integrin, confirming the specificity of the tumor uptake in vivo. These results suggest that [68Ga]NOTA-RGD is a promising candidate for PET imaging of αvβ3 integrin expression in PCa and warrant further in vivo validations to ascertain its potential as an imaging agent for clinical use. The simple and fast preparation of [68Ga]NOTA-RGD may greatly facilitate its translation to a clinical setting.


Angiogenesis, &#945;<sub>v</sub>&#946;<sub>3</sub> integrin, [<sup>68</sup>Ga]NOTA-RGD, PET imaging, prostate cancer.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 4
First Page: 371
Last Page: 379
Page Count: 9
DOI: 10.2174/1568009614666140403123452
Price: $58
Orphan Drugs and Rare Diseases Europe 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science